Cisplatin and TRAIL enhance breast cancer stem cell death

International Journal of Oncology

Volumn 39, Issue 4, 2011, Pages 891-898

  Yin, Shuping ^a   Xu, Liping ^a   Bandyopadhyay, Sudeshna ^a   Sethi, Seema ^a   Reddy, Kaladhar B ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cancer stem cells; Cisplatin; TRAIL; Triple negative breast tumors

Indexed keywords

ALDEHYDE DEHYDROGENASE; BETA CATENIN; CELL SURFACE MARKER; CISPLATIN; CYCLIN D1; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HERMES ANTIGEN; INIPARIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OLAPARIB; PACLITAXEL; PROGESTERONE RECEPTOR; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; WNT1 PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER STEM CELL; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN CRL 2335; CELL STRAIN MDA MB 468; CELL SURVIVAL; CELL VIABILITY; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAMMOSPHERE FORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BETA CATENIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; CYCLIN D1; DRUG SYNERGISM; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; WNT1 PROTEIN;

EID: 79960882206     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1085     Document Type: Article

References (43)

1. Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. N Engl J Med 363: 1938-1948, 2010.
2. Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295: 2492-2502, 2006. (Pubitemid 43854964)
3. Dent R, Trudeau M, Pritchard KI, et al: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434, 2007. (Pubitemid 47219710)
4. Haffty BG, Yang Q, Reiss M, et al: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24: 5652-5657, 2006. (Pubitemid 46631305)
5. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF and Ellis IO: Prognostic markers in triple-negative breast cancer. Cancer 109: 25-32, 2007. (Pubitemid 46120191)
6. Tischkowitz M, Brunet JS, Begin LR, et al: Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7: 134, 2007.
7. McDermott SP and Wicha MS: Targeting breast cancer stem cells. Mol Oncol 4: 404-419, 2010.
8. + breast cancer-initiating cells to radiation. J Natl Cancer Inst 98: 1777-1785, 2006.
9. Yu F, Yao H, Zhu P, et al: let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131: 1109-1123, 2007. (Pubitemid 350235025)
10. Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768, 2008.
11. Liu S, Dontu G and Wicha MS: Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res 7: 86-95, 2005. (Pubitemid 40704127)
12. Reya T and Clevers H: Wnt signalling in stem cells and cancer. Nature 434: 843-850, 2005. (Pubitemid 40558990)
13. Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM and Wicha MS: Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 6: R605-R615, 2004.
14. Liu S, Dontu G, Mantle ID, et al: Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 66: 6063-6071, 2006.
15. Dievart A, Beaulieu N and Jolicoeur P: Involvement of Notch1 in the development of mouse mammary tumors. Oncogene 18: 5973-5981, 1999. (Pubitemid 29535009)
16. Morin PJ, Sparks AB, Korinek V, et al: Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275: 1787-1790, 1997. (Pubitemid 27136715)
17. Clarke MF and Fuller M: Stem cells and cancer: two faces of eve. Cell 124: 1111-1115, 2006.
18. Liu S and Wicha MS: Targeting breast cancer stem cells. J Clin Oncol 28: 4006-4012, 2010.
19. Dontu G, Abdallah WM, Foley JM, et al: In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17: 1253-1270, 2003. (Pubitemid 36583168)
20. Nabha SM, Glaros S, Hong M, et al: Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells. Oncogene 24: 3166-3176, 2005. (Pubitemid 40695085)
21. Visscher DW, Sarkar FH, Kasunic TC and Reddy KB: Clinicopathologic analysis of amphiregulin and heregulin immunostaining in breast neoplasia. Breast Cancer Res Treat 45: 75-80, 1997. (Pubitemid 27338534)
22. Yin S, Sethi S and Reddy KB: Protein kinase Cdelta and caspase-3 modulate TRAIL-induced apoptosis in breast tumor cells. J Cell Biochem 111: 979-987, 2010.
23. Kerfoot C, Huang W and Rotenberg SA: Immunohistochemical analysis of advanced human breast carcinomas reveals downregulation of protein kinase C alpha. J Histochem Cytochem 52: 419-422, 2004. (Pubitemid 38229108)
24. Fong PC, Boss DS, Yap TA, et al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134, 2009.
25. Tutt A, Robson M, Garber JE, et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376: 235-244, 2010.
26. Cleator S, Heller W and Coombes RC: Triple-negative breast cancer: therapeutic options. Lancet Oncol 8: 235-244, 2007. (Pubitemid 46291713)
27. Reddy KB: Triple-negative breast cancer: an updated review on treatment options. Curr Oncol (In press).
28. Wang J, Wakeman TP, Lathia JD, et al: Notch promotes radioresistance of glioma stem cells. Stem Cells 28: 17-28, 2010.
29. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA and Rosen JM: WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA 104: 618-623, 2007. (Pubitemid 46123074)
30. Liedtke C, Mazouni C, Hess KR, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26: 1275-1281, 2008.
31. Tan DS, Marchio C, Jones RL, et al: Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 111: 27-44, 2008. (Pubitemid 352009225)
32. Rakha EA, Reis-Filho JS and Ellis IO: Basal-like breast cancer: a critical review. J Clin Oncol 26: 2568-2581, 2008.
33. Reis-Filho JS and Tutt AN: Triple negative tumours: a critical review. Histopathology 52: 108-118, 2008. (Pubitemid 350265179)
34. Jordan CT, Guzman ML and Noble M: Cancer stem cells. N Engl J Med 355: 1253-1261, 2006. (Pubitemid 44427449)
35. Pardal R, Clarke MF and Morrison SJ: Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3: 895-902, 2003. (Pubitemid 37500174)
36. Huelsken J, Vogel R, Brinkmann V, Erdmann B, Birchmeier C and Birchmeier W: Requirement for beta-catenin in anterior-posterior axis formation in mice. J Cell Biol 148: 567-578, 2000.
37. Kelly OG, Pinson KI and Skarnes WC: The Wnt co-receptors Lrp5 and Lrp6 are essential for gastrulation in mice. Development 131: 2803-2815, 2004. (Pubitemid 39004073)
38. Soriano JV, Uyttendaele H, Kitajewski J and Montesano R: Expression of an activated Notch4(int-3) oncoprotein disrupts morphogenesis and induces an invasive phenotype in mammary epithelial cells in vitro. Int J Cancer 86: 652-659, 2000. (Pubitemid 30249875)
39. Ricci-Vitiani L, Fabrizi E, Palio E and De Maria R: Colon cancer stem cells. J Mol Med 87: 1097-1104, 2009.
40. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
41. Abratt RP, Brune D, Dimopoulos MA, et al: Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Ann Oncol 15: 1613-1621, 2004. (Pubitemid 39562600)
42. Huff CA, Matsui W, Smith BD and Jones RJ: The paradox of response and survival in cancer therapeutics. Blood 107: 431-434, 2006. (Pubitemid 43076361)
43. Rocha Lima CM, Green MR, Rotche R, et al: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22: 3776-3783, 2004. (Pubitemid 41095218)